Dongdao Pharmaceuticals anti-VEGF single anti-phase 3 clinical fdam is approved by the FDA

TAB014 is an antibody based on beva bead monoantibodies that can be used to treat wet (vascular) age-related macular degeneration, retinal venous obstruction (RVO), vascular nasal vascular (CNV), and other eye diseases.
beva bead monoantin is a clinically proven anti-VEGF drug.
Ophthalmology has obtained an exclusive license from Dongxuan Pharmaceuticals to commercialize TAB014 in China for the treatment of angiopathic eye diseases associated with angiogenesy.
, TAB014 is currently conducting clinical studies in China on wet age-related macular degeneration.
according to the announcement, the IND application in the United States is based on TAB014 Phase 1 clinical trial data and relevant clinical literature in China, directly applying for Phase 3 clinical trial license (exempt from Phase 2 clinical trials), the adaptive wAMD.
this is also the first project in China to submit an IND application and be licensed overseas, which is of great significance for Dongding Pharmaceuticals to enter the international market.
pathological characteristics of age-related macular degeneration of wetting (new blood vessels) are vascultural angiogenesia in the macular region, and VEGF plays an important role in its angiogenesic process.
announcement shows that TAB014 is able to bind specifically to VEGF and prevent it from binding to the subject, thereby inhibiting angiogenesty.
TAB014 will eventually be used to treat wAMD by glass injection, promising to bring a new treatment option to patients.